Intravenous immunoglobulin (IVIg) has long been used as an immunomodulatory agent for a wide range of immune and inflammatory disorders in clinical specialties including neurology, hematology, immunology, nephrology, rheumatology, and dermatology.1 Today, many researchers are exploring the potential for using existing IVIg treatments for severely ill COVID-19 patients, as well as exploring the development of new hyper-immune globulins to treat severe infections. Learn more in the following white paper.
A white paper on the potential of intravenous immunoglobulin (IVIg) to treat severe COVID-19 patients.
Summary:COVID-19 was declared a global pandemic in March 2020. The number of cases continues to rise producing an unprecedented global health and economic crisis.
Rapid progression of lung involvement in patients with severe COVID-19, and lack of definitive, effective treatment, make it imperative to develop efficient therapeutic strategies. The point at which pulmonary deterioration starts is a critical window of opportunity for intervention. The ability to halt lung injury and reduce the need for mechanical ventilation would be of great benefit to healthcare systems worldwide. Therefore, it may be useful to consider high-dose intravenous immunoglobulin (IVIg) at the start of respiratory distress to promote potential recovery and reduce the burden of care for COVID-19 patients.